[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2007/49041,2007,A1Locationinpatent:Page/Pagecolumn43
[2]Locationinpatent:experimentalpartIoannidis,Stephanos;Lamb,MichelleL.;Wang,Tao;Almeida,Lynsie;Block,MichaelH.;Davies,AudreyM.;Peng,Bo;Su,Mei;Zhang,Hai-Jun;Hoffmann,Ethan;Rivard,Caroline;Green,Isabelle;Howard,Tina;Pollard,Hannah;Read,Jon;Alimzhanov,Marat;Bebernitz,Geraldine;Bell,Kirsten;Ye,Minwei;Huszar,Dennis;Zinda,Michael[JournalofMedicinalChemistry,2011,vol.54,#1,p.262-276]
[1]Ioannidis,Stephanos;Lamb,MichelleL.;Wang,Tao;Almeida,Lynsie;Block,MichaelH.;Davies,AudreyM.;Peng,Bo;Su,Mei;Zhang,Hai-Jun;Hoffmann,Ethan;Rivard,Caroline;Green,Isabelle;Howard,Tina;Pollard,Hannah;Read,Jon;Alimzhanov,Marat;Bebernitz,Geraldine;Bell,Kirsten;Ye,Minwei;Huszar,Dennis;Zinda,Michael[JournalofMedicinalChemistry,2011,vol.54,#1,p.262-276]
[1]Locationinpatent:experimentalpartIoannidis,Stephanos;Lamb,MichelleL.;Wang,Tao;Almeida,Lynsie;Block,MichaelH.;Davies,AudreyM.;Peng,Bo;Su,Mei;Zhang,Hai-Jun;Hoffmann,Ethan;Rivard,Caroline;Green,Isabelle;Howard,Tina;Pollard,Hannah;Read,Jon;Alimzhanov,Marat;Bebernitz,Geraldine;Bell,Kirsten;Ye,Minwei;Huszar,Dennis;Zinda,Michael[JournalofMedicinalChemistry,2011,vol.54,#1,p.262-276]
[1]Locationinpatent:experimentalpartIoannidis,Stephanos;Lamb,MichelleL.;Wang,Tao;Almeida,Lynsie;Block,MichaelH.;Davies,AudreyM.;Peng,Bo;Su,Mei;Zhang,Hai-Jun;Hoffmann,Ethan;Rivard,Caroline;Green,Isabelle;Howard,Tina;Pollard,Hannah;Read,Jon;Alimzhanov,Marat;Bebernitz,Geraldine;Bell,Kirsten;Ye,Minwei;Huszar,Dennis;Zinda,Michael[JournalofMedicinalChemistry,2011,vol.54,#1,p.262-276]
[1]OrganicProcessResearchandDevelopment,2013,vol.17,p.1123-1130
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
Journal: Oncotarget 20120901
Title: Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
Journal: Neoplasia (New York, N.Y.) 20120101
Title: Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.
Journal: Journal of medicinal chemistry 20110526
Title: Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway.
Journal: Journal of medicinal chemistry 20110113
Title: The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies.
Journal: Surgical neurology international 20110101
Title: Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.
Journal: The Journal of biological chemistry 20081121
Title: Derenzini E, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011 Dec;1(12):e46.
Title: Scuto A, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011 Mar;25(3):538-50.
Title: McFarland BC, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011 Dec;10(12):2384-93.
Title: Xin H, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 1;71(21):6601-10.
Title: Hedvat M, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-9
Title: Ni J, et al. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 Jan;19(1):22-30.
